The Blood Coagulants Market is expected to grow at the CAGR of 9.5% during the forecast period 2017-2023.

Blood Coagulants Market Scenario:

Coagulation is the process, by which blood changes from a liquid to a gel, forming a blood clot. In general terms, coagulation is a process in which the blood forms clots to block and then heal a lesion/wound/cut and stop the bleeding. The Middle East & Africa blood coagulant market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. In the Middle East and Sub-Saharan Africa, bleeding disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/2743 .

As per the study published in Blood Coagulation Fibrinolysis journal, 2016, it is reported that in the Yaoundé Hemophilia Treatment Center (HTC) of Cameroon multiple cases of hemophilia and von willebrand disease (VWD) have been registered According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH), in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 with other bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years A  research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia in Saudi Arabia and most dominant in male patients: 1 : 5000 to 10,000. Whereas, prevalence rate of hemophilia B: 1: 34,500 male patients

Key Players for EMEA Blood Coagulants Market:

Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), and CSL Limited (Australia).

Blood Coagulants Market Segmentation                                                                                                                               The MEA blood coagulants market is segmented on the basis of types, indications, and by country.

On the basis of types, the market is segmented into coagulation factor and others. Coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.

On the basis of indication, the market is segmented into haemophilia, surgery, other bleeding disorders, and others. Haemophilia is further divided into haemophilia A and haemophilia B.

On the basis of country, the market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of Middle East & Africa.

Blood Coagulants Market Regional Analysis                               

The Middle East & Africa blood coagulants market is segmented on the basis of countries into Saudi Arabia (KSA), United Arab Emirates (UAE), Qatar, Oman, Kuwait, Egypt, and rest of Middle East & Africa.

Saudi Arabia has the largest market share of the Middle East & Africa blood coagulants market by countries in 2016.

The large share is majorly attributed to increasing prevalence of the haemophilia disease in this country, high usage of the expensive recombinant coagulation factors for the treatment, and high disposable income of the population, and better healthcare facilities in this country.

Ask Questions to Expertise @https://www.marketresearchfuture.com/enquiry/2743 

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: [email protected]